Cogstate (ASX:CGS) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CGS Cogstate Ltd ASX:CGS
76 GF Score
Price A$2.88
GF Value A$2.12
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cogstate Net Loan?

Net Loan only applies to banks and insurance companies.

ASX:CGS
76GF Score
Cogstate Ltd ASX:CGS
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cogstate (ASX:CGS) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of A$2.88 is trading 35.8% above its estimated GF Value™ of A$2.12. GuruFocus considers Cogstate to be Significantly Overvalued.

Key valuation signals for ASX:CGS:

  • Net Loan:
  • GF Value™: A$2.12 vs. price of A$2.88 (35.8% above fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cogstate Business Description

Other Exchanges COGZF:USAC4B:Germany
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
76GF Score

Get the complete analysis for ASX:CGS

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.88
Price
A$2.12
GF Value